.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 9,072,680

« Back to Dashboard

Details for Patent: 9,072,680

Title:Compositions comprising methylphenidate complexed with ion-exchange resin particles
Abstract: Pharmaceutical compositions of methylphenidate complexed with ion-exchange resin particles to form drug-resin particles are provided. The compositions have a first plurality of drug-resin particles that are uncoated and a second plurality of drug-resin particles that are coated with a delayed release coating. Preferably, the second plurality of drug-resin particles are coated with a triggered-release coating triggered by a pH change and a diffusion barrier coating.
Inventor(s): Tengler; Mark (Colleyville, TX), McMahen; Russell (Flower Mound, TX)
Assignee: NEOS THERAPEUTICS, LLP (Grand Prairie, TX)
Filing Date:Mar 15, 2013
Application Number:13/844,584
Claims:1. A pharmaceutical composition comprising an ADHD effective agent complexed with ion-exchange resin particles to form drug-resin particles, wherein said ADHD effective agent is methylphenidate, wherein said composition comprises a first plurality of drug-resin particles that provide for immediate release of said ADHD effective agent and a second plurality of drug-resin particles that are coated with a triggered-release coating triggered by a pH change and a diffusion barrier coating, and wherein administration of the composition to a human produces a mean plasma concentration profile for d-methylphenidate in human subjects which has one or more parameters selected from the group consisting of AUC.sub.0-3, AUC.sub.0-5, AUC.sub.0-Tmax, AUC.sub.5-12, AUC.sub.5-24, AUC.sub.Tmax-24, AUC.sub.Tmax-12, AUC.sub.5-t, AUC.sub.Tmax-t, AUC.sub.0-24, and AUC.sub.0-.infin. which is substantially similar to those parameters of at least one of the in vivo serum profiles of the compositions comprising methylphenidate-containing drug-resin particles shown in FIG. 20A.

2. The composition of claim 1, wherein the triggered-release coating is cellulose acetate phthalate, cellulose acetate trimellitate, hydroxypropyl methylcellulose phthalate, polyvinyl acetate phthalate, carboxymethylethylcellulose, co-polymerized methacrylic acid/methacrylic acid methyl esters, co-polymerized methacrylic acid/acrylic acid ethyl esters, or mixtures thereof.

3. The composition of claim 2, wherein the composition additionally contains polistirex, polacrilex, cholestyramine, polacrilin or mixtures thereof.

4. The composition of claim 1, wherein the diffusion barrier coating contains polyvinylpyrrolidone, polyvinylacetate, polyvinylalcohol or mixtures thereof.

5. The composition of claim 1, wherein the diffusion barrier coating is a water insoluble, water permeable membrane.

6. The composition of claim 5, wherein the water insoluble, water permeable membrane is ethylcellulose.

7. The composition of claim 1, wherein the triggered-release coating covers the diffusion barrier coating.

8. The composition of claim 7, wherein the diffusion barrier coating is ethylcellulose.

9. The composition of claim 1, wherein the resin particles are strong acidic cation exchange resins, selected from the group consisting of polistirex, polacrilex, cholestyramine, polacrilin and mixtures thereof.

10. The composition of claim 1, wherein said first plurality of particles comprise 20%-30% by number of the drug-resin particles present in said composition and said second plurality of particles comprise 70%-80% by number of the drug-resin particles present in said composition.

11. The composition of claim 8, wherein said first plurality of particles comprise about 25% by number of the drug-resin particles present in said composition and said second plurality of particles comprise about 75% by number of the drug-resin particles present in said composition.

12. The composition of claim 1, wherein the composition is a liquid suspension, chewable composition, or an orally disintegrating tablet composition.

13. The composition of claim 1, wherein the amount of methylphenidate is 10-60 mg.

14. The composition of claim 1, wherein the composition has an in vitro dissolution profile wherein 30-33% by weight of the ADHD effective agent is released from the drug-resin particles within the first 30 minutes, 34-42% by weight of the agent is released within 2 hours, 40-80% of the agent is released within 4 hours, and 80-100% by weight of the agent is released within 24 hours, wherein the dissolution profile is determined by an in vitro dissolution assay, wherein the conditions of the dissolution assay are an initial dissolution medium of 0.1 N HCl, and after 2 hours, the medium is adjusted to a pH of about 6.8; and the dissolution assay is performed using a USP Apparatus 2.

15. The composition of claim 1, wherein the composition has an in vivo serum profile that is statistically similar to at least one profile selected from FIGS. 27A, 27B, 28A, and 28B.

16. The composition of claim 1, wherein a mammal receiving said composition, in the presence of ethanol, is exposed to a reduced amount of methylphenidate compared to an extended release composition without resin particles comprising methylphenidate hydrochloride.

17. The composition of claim 1, wherein the amount of said methylphenidate in said composition is equivalent to the amount present in a 10 mg, 20 mg, 30 mg, 40 mg, 50 mg or 60 mg dose of methylphenidate hydrochloride.

18. The composition of claim 1, wherein said composition is an orally disintegrating tablet and is effective to provide a mean plasma concentration profile in human adult ADHD patients which has an AUC.sub.0-3 of 20.53 ng hr/mL -20%/+25% and a C.sub.max of 20.17 ng/mL -20%/+25% for d-methylphenidate, an AUC.sub.0-3 of 0.62 ng hr/mL -20%/+25% and a C.sub.max of 0.44 ng/mL -20%/+25% for l-methylphenidate, and/or an AUC.sub.0-3 of 21.29 ng hr/mL -20%/+25% and a C.sub.max of 20.60 ng/mL -20%/+25% for total methylphenidate, for a total methylphenidate dose that is equivalent to the amount present in a 60 mg total dose of methylphenidate hydrochloride, or respective AUC and C.sub.max values directly proportional thereto for a total methylphenidate dose other than that which is equivalent to the amount present in a 60 mg total dose of methylphenidate hydrochloride.

19. The composition of claim 1, wherein said composition is an orally disintegrating tablet and is effective to provide a mean plasma concentration profile in human adult ADHD patients which has an AUC.sub.0-5 of 50.16 ng hr/mL -20%/+25% and a C.sub.max of 20.17 ng/mL -20%/+25% for d-methylphenidate, an AUC.sub.0-5 of 1.07 ng hr/mL -20%/+25% and a C.sub.max of 0.44 ng/mL -20%/+25% for l-methylphenidate, and/or an AUC.sub.0-5 of 51.43 ng hr/mL -20%/+25% and a C.sub.max of 20.60 ng/mL -20%/+25% for total methylphenidate, for a total methylphenidate dose that is equivalent to the amount present in a 60 mg total dose of methylphenidate hydrochloride, or respective AUC and C.sub.max values directly proportional thereto for a total methylphenidate dose other than that which is equivalent to the amount present in a 60 mg total dose of methylphenidate hydrochloride.

20. The composition of claim 1, wherein said composition is an orally disintegrating tablet and is effective to provide a mean plasma concentration profile in human adult ADHD patients which has an AUC.sub.5-24 of 103.84 ng hr/mL -20%/+25% and a C.sub.max of 20.17 ng/mL -20%/+25% for d-methylphenidate, an AUC.sub.5-24 of 0.96 ng hr/mL -20%/+25% and a C.sub.max of 0.44 ng/mL -20%/+25% for l-methylphenidate, and/or an AUC.sub.5-24 of 105.07 ng hr/mL -20%/+25% and a C.sub.max of 20.60 ng/mL -20%/+25% for total methylphenidate, for a total methylphenidate dose that is equivalent to the amount present in a 60 mg total dose of methylphenidate hydrochloride, or respective AUC and C.sub.max values directly proportional thereto for a total methylphenidate dose other than that which is equivalent to the amount present in a 60 mg total dose of methylphenidate hydrochloride.

21. The composition of claim 1, wherein said composition is an orally disintegrating tablet and is effective to provide a mean plasma concentration profile in human adult ADHD patients which has an AUC.sub.0-24 of 156.72 ng hr/mL -20%/+25% and a C.sub.max of 20.17 ng/mL -20%/+25% for d-methylphenidate, an AUC.sub.0-24 of 2.19 ng hr/mL -20%/+25% and a C.sub.max of 0.44 ng/mL -20%/+25% for l-methylphenidate, and/or an AUC.sub.0-24 of 159.25 ng hr/mL -20%/+25% and a C.sub.max of 20.60 ng/mL -20%/+25% for total methylphenidate, for a total methylphenidate dose that is equivalent to the amount present in a 60 mg total dose of methylphenidate hydrochloride, or respective AUC and C.sub.max values directly proportional thereto for a total methylphenidate dose other than that which is equivalent to the amount present in a 60 mg total dose of methylphenidate hydrochloride.

22. The composition of claim 1, wherein said composition, would produce, in a human adult, a mean plasma concentration versus time curve (ng/ml versus hours) having an area under the curve (AUC.sub.0-.infin.) of about 160 ng hr/ml to about 180 ng hr/ml for total methylphenidate when said composition contains a total methylphenidate dose that is equivalent to that present in about a 60 mg total dose of methylphenidate hydrochloride.

23. The composition of claim 1, wherein one or more in vivo pharmacokinetic parameters of the composition selected from the group consisting of C.sub.max, AUC.sub.0-3, AUC.sub.O-5, AUC.sub.0-Tmax, AUC.sub.5-12, AUC.sub.5-24, AUC.sub.Tmax-24, ACU.sub.Tmax-12, AUC.sub.5-t, AUC.sub.Tmax-t, AUC.sub.0-24, and AUC.sub.0-.infin. have a 90% confidence interval with upper and lower bounds within a range from 90%-115% of the value of the same parameter(s) for a bioequivalent reference composition.

24. The composition of claim 1, wherein said composition has an in vivo serum profile with a T.sub.max of approximately six hours.

25. The composition of claim 24, wherein said composition has a bimodal profile with two peaks, having a first peak at approximately 3 hours.

26. The composition of claim 1, wherein said composition has an in vivo serum profile with a first and second peak and said second peak is the C.sub.max.

27. The composition of claim 1, wherein a dose of said composition comprising a total amount of said methylphenidate that is equivalent to that present in about a 60 mg total dose of methylphenidate hydrochloride produces a C.sub.max greater than 16.55 ng/mL.

28. The composition of claim 1, wherein said first plurality of drug-resin particles is uncoated.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc